Niraparib

Niraparib 2D Structure
Brand name: Zejula
IUPAC: 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
FDA approval: Yes
Usage:

Niraparib is a once daily oral medication, which is mostly used in the treatment of ovarian cancers.  It is also used in treatment of fallopian tube, or primary peritoneal cancers.1

  • 1. TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about
Mechanism:

Niraparib works as a by inhibiting an enzym called poly ADP ribose polymerase (PARP).  This process allows for the destruction of cancerous cell DNA, which in turns leads to apoptosis.1

 

Niraparib

  • 1. TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about
Side effects:

The most common side effects associated with niraparib include: nausea, low white and red blood cell counts, fatigue and constipation.1

  • 1. TESARO, I. (n.d.). ZEJULA Is a Once-Daily Oral PARP Inhibitor1. Retrieved July 16, 2017, from http://zejula.com/about